Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.

X-linked SCID (SCID-X1) is amenable to correction by gene therapy using conventional gammaretroviral vectors. Here, we describe the occurrence of clonal T cell acute lymphoblastic leukemia (T-ALL) promoted by insertional mutagenesis in a completed gene therapy trial of 10 SCID-X1 patients. Integration of the vector in an antisense orientation 35 kb upstream of the protooncogene LIM domain only 2 (LMO2) caused overexpression of LMO2 in the leukemic clone. However, leukemogenesis was likely precipitated by the acquisition of other genetic abnormalities unrelated to vector insertion, including a gain-of-function mutation in NOTCH1, deletion of the tumor suppressor gene locus cyclin-dependent kinase 2A (CDKN2A), and translocation of the TCR-beta region to the STIL-TAL1 locus. These findings highlight a general toxicity of endogenous gammaretroviral enhancer elements and also identify a combinatorial process during leukemic evolution that will be important for risk stratification and for future protocol design.

[1]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[2]  L. Notarangelo,et al.  Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement , 2002, Nature Medicine.

[3]  W. Leonard,et al.  Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans , 1993, Cell.

[4]  N. Copeland,et al.  Gene Therapy Insertional Mutagenesis Insights , 2004, Science.

[5]  Rafael A Irizarry,et al.  Exploration, normalization, and genotype calls of high-density oligonucleotide SNP array data. , 2006, Biostatistics.

[6]  F. Gotch,et al.  T‐cell re‐population in HIV‐infected children on highly active anti‐retroviral therapy (HAART) , 2001, Clinical and experimental immunology.

[7]  J. Aster,et al.  Leukemia-Associated Mutations within the NOTCH1 Heterodimerization Domain Fall into at Least Two Distinct Mechanistic Classes , 2006, Molecular and Cellular Biology.

[8]  Christof von Kalle,et al.  and insertional genotoxicity Cell culture assays reveal the importance of retroviral vector design for , 2006 .

[9]  Tactggtat Agcctagatgtgtttaga,et al.  J-mediated Translocations in Lymphoid Neoplasms : A Functional Assessment of Genomic Instability by Cryptic Sites , 2001 .

[10]  Zhiyuan Luo,et al.  Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia , 2005, British journal of haematology.

[11]  T. Lu,et al.  Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Clelia Di Serio,et al.  Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration , 2006, Nature Biotechnology.

[13]  N. Tanaka,et al.  Cloning of the gamma chain of the human IL-2 receptor. , 1992, Science.

[14]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[15]  T. Rabbitts,et al.  The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  Alessandro Aiuti,et al.  Hot spots of retroviral integration in human CD34+ hematopoietic cells. , 2007, Blood.

[17]  David A. Williams,et al.  Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  F. Deist,et al.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.

[19]  Kathryn L. Parsley,et al.  Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  M. Eguchi,et al.  NOTCH1 mutation can be an early, prenatal genetic event in T-ALL. , 2008, Blood.

[21]  Christine Kinnon,et al.  Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. , 2007, The Journal of clinical investigation.

[22]  Christof von Kalle,et al.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. , 2003, The New England journal of medicine.

[23]  Yang Du,et al.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.

[24]  L. Foroni,et al.  Notch-1 Mutations Are Secondary Events in Some Patients with T-Cell Acute Lymphoblastic Leukemia , 2007, Clinical Cancer Research.

[25]  Shawn M. Burgess,et al.  Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration , 2003, Science.

[26]  M. Reinders,et al.  Ectopic retroviral expression of LMO2, but not IL2Rγ, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy , 2007, Leukemia.

[27]  Dick de Ridder,et al.  New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling , 2005, The Journal of experimental medicine.

[28]  Christine Kinnon,et al.  Mutations in TNFRSF13B Encoding TACI Are Associated With Common Variable Immunodeficiency in Humans , 2006, Pediatrics.

[29]  N. Greenberg,et al.  NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. , 2008, Immunity.

[30]  A. Fischer,et al.  Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. , 2002, The New England journal of medicine.

[31]  J. Barata,et al.  Interleukin-7 in T-cell acute lymphoblastic leukemia: An extrinsic factor supporting leukemogenesis? , 2005, Leukemia & lymphoma.

[32]  A. Schambach,et al.  Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells , 2007, Blood.

[33]  Hanno Glimm,et al.  High-resolution insertion-site analysis by linear amplification–mediated PCR (LAM-PCR) , 2007, Nature Methods.

[34]  F. Alt,et al.  Activating Notch1 mutations in mouse models of T-ALL. , 2005, Blood.

[35]  T. Rabbitts,et al.  The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. , 1995, Oncogene.

[36]  Bruce Aronow,et al.  Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. , 2007, The Journal of clinical investigation.

[37]  F. Bushman,et al.  Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.

[38]  A. Mortellaro,et al.  Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.

[39]  A. Look,et al.  Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia , 2006, Nature Reviews Cancer.